We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.
Oruka Therapeutics
Biotechnology Research
A new era for chronic skin diseases
About us
Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions
- Website
-
www.orukatx.com
External link for Oruka Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Public Company
Employees at Oruka Therapeutics
Updates
-
We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.
-
We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million | Tue, 09/03/2024 - 07:00
ir.orukatx.com